<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

thenextweb
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseases are treated. Candid Therapeutics is two years old. It does not have an approved drug. Its lead programme has been tested […]<br /> This story continues at The Next Web [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
What’s going on with Donut Lab?

In January, a Finnish-Estonian startup proclaimed it had developed a truly solid state battery, a holy grail for the technology industry. Donut Labs’ cell wasn’t just solid state, however. It clai [...]

Match Score: 164.21

qz
UCB is snapping up U.S. autoimmune biotech Candid Therapeutics for $2.2 billion

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune diseases [...]

Match Score: 139.44

Destination
Another big car company gives up on hydrogen

Stellantis, the automotive giant behind Chrysler, Citroen, Fiat, Jeep and Peugeot, is pulling out of hydrogen. The company said it’s killing its fuel cell development program in the face of “limi [...]

Match Score: 64.95

Destination
A revolutionary cancer treatment could transform autoimmune disease

Researchers are testing CAR T cell therapy as a way to reset the immune system. [...]

Match Score: 47.83

Destination
Netflix's Splinter Cell: Deathwatch animated series arrives on October 14

Ubisoft still isn’t giving us a new Splinter Cell game, but Sam Fisher fans are at least getting an animated TV adaptation very soon. At this week’s Anime NYC convention, Netflix revealed a new te [...]

Match Score: 46.39

thenextweb
Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by e [...]

Match Score: 41.99

thenextweb
Britain is spending £2bn to train its army inside an AI war simulation

Britain is spending £2bn to train its army inside a simulation. It has handed the job to an American defence giant, with a German one taking a slice. The UK has signed a £2bn ($2.7bn) contract to tr [...]

Match Score: 41.43

thenextweb
Lenovo taps $2bn convertible market to refinance and buy back stock

Lenovo has raised $2bn through seven-year convertible bonds, and the most notable thing about the debt is that it pays nothing. The Beijing-based maker of computers and AI servers sold zero-coupon not [...]

Match Score: 38.11

Destination
Peter Thiel is utterly wrong about Alzheimer's

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion sect [...]

Match Score: 36.48